<DOC>
	<DOCNO>NCT01947777</DOCNO>
	<brief_summary>To evaluate effect rifampin , cytochrome P450 3A ( CYP3A ) inducer , pharmacokinetics ( PK ) IPI-145 ; assess safety tolerability IPI-145 administer rifampin healthy subject</brief_summary>
	<brief_title>Phase 1 Study Healthy Subjects Evaluate Effect Rifampin Pharmacokinetics IPI-145</brief_title>
	<detailed_description>- In Treatment Period 1 , subject receive single 25 mg oral dose IPI-145 - In Treatment Period 2 , Days 3-9 , subject receive daily ( QD ) oral dose 600 mg rifampin ; Day 9 , subject receive single oral dose 25 mg IPI-145 concomitantly administer 600 mg rifampin</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy men woman nonchildbearing potential 1850 year age Body Mass Index ( BMI ) : 18.0 32.0 kg/m2 In good health , determine clinically significant finding clinical evaluation Provided write informed consent prior study specific procedure Women childbearing potential Evidence clinically significant medical condition History gastrointestinal disease surgery may affect drug absorption Positive indeterminate Tuberculosis spot test screen Any active infection time screen admission Consumption nutrient know modulate cytochrome P450 enzyme activity within 14 day prior administration study drug , study , discharge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>DDI</keyword>
	<keyword>CYP3A</keyword>
</DOC>